Evidence map›Paper›PMID 41062649›Full record

ArticleScientific reports2025

Immunohistochemical expression pattern of leukemia inhibitory factor and its receptor may mark a tipping point in the progression of oral cancer.

Muhammed Yakin, Benedict Seo, Haizal Mohd Hussaini, Alison M Rich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muhammed YakinAdelaide Dental School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia. muhammed.yakin@adelaide.edu.au.
Benedict SeoFaculty of Dentistry, Sir John Walsh Research Institute, University of Otago, Dunedin, Otago, New Zealand.
Haizal Mohd HussainiFaculty of Dentistry, Sir John Walsh Research Institute, University of Otago, Dunedin, Otago, New Zealand.
Alison M RichFaculty of Dentistry, Sir John Walsh Research Institute, University of Otago, Dunedin, Otago, New Zealand.

Funding

Charles Sturt University Compact Seed GrantSir John Walsh Research Institute, University of Otago Oral Molecular and Immunopathology Research Group
6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) is an aggressive cancer with 60% survival rate, high mortality, and morbidity. Leukaemia inhibitory factor (LIF) and its receptor (LIF-R) are involved in the activation of the signal transducer and activator of transcription-3 (STAT3) pathway which has central involvement in the signalling pathways involved in important pathological processes including carcinogenesis and inflammation. STAT3 and its activators have shown prognostic significance in OSCC. The aim is to evaluate the immunohistochemical (IHC) expression of LIF and LIF-R proteins in OSCC. Four tissue microarrays (TMA) including OSCC (n = 95) and normal oral mucosa (NOM; n = 11) as control tissue were used in this study. FIJI software was for semi-quantitative analysis of IHC expression of LIF and LIF-R. Statistical analysis were performed using SPSS. LIF-R was expressed to a significantly higher extent in OSCC compared to NOM (p = 0.02) and LIF was expressed to a significantly higher extent in NOM compared to OSCC (p < 0.001) and in the buccal mucosa compared to the gingiva/alveolar mucosa (p = 0.022) and the lip vermilion (p = 0.17). No other significant differences were found in LIF and LIF-R expression when OSCC were compared according to site, grade, or stage. This is the first study to confirm the expression of LIF in OSCC and NOM. The biphasic lower expression of LIF and higher expression of LIF-R in OSCC may indicate a key point of differentiation between NOM and OSCC. The downregulation of LIF expression may be an indication of promotion towards malignancy.

Indexed as

Carcinoma, Squamous CellLeukemia Inhibitory FactorLeukemia Inhibitory Factor Receptor alpha SubunitMouth NeoplasmsReceptors, OSM-LIFAdultAgedAged, 80 and overBiomarkers, TumorDisease ProgressionFemaleHumansImmunohistochemistryMaleMiddle AgedMouth MucosaBiomarkers, TumorLeukemia Inhibitory FactorLeukemia Inhibitory Factor Receptor alpha SubunitLIF protein, humanLIFR protein, humanReceptors, OSM-LIFSTAT3 protein, humanSTAT3 Transcription FactorImmunohistochemistryOral cancerTissue microarrays

Identifiers

PMID41062649
PMCPMC12508188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.